Summary Sustained use of non-steroidal anti-inflammatory drugs (NSAIDs) may prevent colorectal cancer. However, the optimal drug, period of efficacy and mechanism(s) of action are unknown. Experiments were undertaken to determine which of several NSAIDs would modulate colon crypt cell proliferation or apoptosis when given during the initiation phase of 1,2-dimethylhydrazine (DMH)-induced rat colon cancer. Colon crypts located both away from and over an aggregate of lymphoid nodules (ALN) were examined. Rats were injected with aspirin, indomethacin, nabumetone, sodium salicylate, 16,16-dimethyl prostaglandin E2 or saline for 3 days and DMH or DMH vehicle on day 4 of each week for 8 weeks, then killed 3 days after the last DMH injection. At the time of killing, DMH had significantly increased crypt cell proliferation but not apoptosis. There was significantly more cell proliferation and apoptosis in crypts over the ALN than away from the ALN. Aspirin and salicylate increased proliferation and apoptosis in crypts over the ALN. Finally, the distributional peaks of cell proliferation and apoptosis were shifted significantly closer together after DMH. Thus, DMH increases proliferation and alters the distribution of proliferating and apoptotic cells in colon crypts early in carcinogenesis. Aspirin may suppress tumour incidence via salicylate by enhancing apoptosis in carcinogen-initiated cells.
PGHS-1 and PGHS-2 (Meade et al, 1993) . PGHS-l is the constitutive form of the enzyme and is expressed in most tissues, whereas PGHS-2 is induced by mitogenic stimuli in inflammatory situations (Smith and DeWitt, 1996) and is expressed at high levels in colon tumour tissue (Eberhart et al, 1994; Kargman et al, 1995; Dubois et al, 1996) . Aspirin covalently and irreversibly modifies the cyclo-oxygenase active site of both PGHS-1 and PGHS-2 by acetylation, whereas other NSAIDs reversibly block PGHS function and thus prostaglandin production via steric hindrance of the cyclo-oxygenase active site (Smith and DeWitt, 1996) .
Several lines of evidence implicate prostaglandin (PG) involvement in colorectal cancer (Marnett, 1992) . These include: evidence that PGs stimulate proliferation of human colon cancer cell lines in vitro and normal rodent colon epithelial tissue in vivo (Qiao et al, 1995) ; evidence that progressively increased tissue prostaglandin EB (PGE2) levels are associated with progression of colon carcinogenesis (Pugh and Thomas, 1994) ; and a possible immunosuppressive effect of PGE2 (Goodwin, 1981) . Thus, NSAID inhibition of intestinal prostaglandin production may have a number of direct chemopreventive activities against the progression of colorectal cancer.
Other potential mechanisms for chemoprevention by NSAIDs include alteration of colon epithelial cell proliferation and/or apoptosis. A tumour is generally considered to be a lesion that arises as a result of an imbalance between cell proliferation and cell death. Increased epithelial cell proliferation is an established risk factor for colon cancer development (Deschner and Maskens, 1982; Wright and Alison, 1984; Cameron et al, 1990) . NSAIDs have been shown to reduce cell proliferative parameters in colon crypts (Barnes et al, 1995) and to stall cultured colon adenocarcinoma cells in the GO/GI phase of the cell cycle (Shiff et al, 1996) .
NSAIDs may also restore normal colon mucosal homeostasis in situations of increased proliferation by inducing apoptotic cell death Shiff et al, 1995; .
This report examines whether NSAIDs, specifically aspirin, indomethacin or nabumetone, would prevent initial preneoplastic changes in colon epithelial cell proliferation or apoptosis when administered only during the initiation phase of 1,2-dimethylhydrazine (DMH)-induced rat colon cancer. Either aspirin and/or its metabolite, salicylic acid, could be the active molecule in colon cancer chemoprevention; thus, this study included both aspirin and sodium salicylate treatment groups. In addition, 16,16-dimethylprostaglandin E, (dmPGE2), a stable PGE, analogue that has been shown to stimulate proliferation of colonocytes both in vitro and in vivo (Qiao et al, 1995) , was tested as a positive control for inhibition of prostaglandin synthesis by NSAIDs. The effects of these drugs on cell proliferation and apoptosis were examined in rat colon crypts located both over the rat distal colon aggregate of lymphoid nodules (ALN, a site of rapid epithelial cell proliferation and of high risk for adenocarcinoma occurrence; Hammann et al, 1992; Cameron et al, 1996) and away from an ALN. Finally, this report demonstrates: (a) the simultaneous use of the cell proliferative and apoptotic indices in colon crypts; and (b) that the distribution of proliferative and apoptotic cells in colon crypts can be used as an early biomarker of neoplastic change.
MATERIALS AND METHODS Animals
Male Sprague-Dawley rats were purchased at 2 months of age from Harlan Sprague-Dawley (Indianapolis, IN, USA) 4 weeks before the experiment. Rats had free access to Teklad ML485 Rat Diet (Teklad/HSD, Madison, WI, USA) and water before and throughout these studies. The rats were housed in wire-bottom cages to prevent coprophagy. All experimental procedures described below were approved by the Institutional Animal Care Program of the University of Texas Health Science Center (San Antonio, TX, USA).
Reagents
The following materials were used in these studies: DMH, acetylsalicylic acid (ASA, aspirin), sodium salicylate, indomethacin, and 16,16-dimethyl-prostaglandin E, (dmPGE2, a stable PGE2 analogue) were purchased from Sigma (St Louis, MO, USA); nabumetone was a generous gift from SmithKline Beecham, King of Prussia, PA, USA; an antiproliferating cell nuclear antigen (PCNA) monoclonal antibody (PC10 clone) was purchased from Signet (Dedham, MA, USA); and the Apoptag kit (purchased from Oncor, Gaithersburg, MD, USA) was used in the TdT UDP nucleotide end-labelling (TUNEL) assay for fragmented DNA ends. All other chemicals were of the highest grade available and were obtained commercially. DMH vehicle contained 0.9% sodium chloride and 0.18% EDTA, pH 6.5, and all other solutions were prepared and diluted with normal saline (0.9% codium chloride solution, pH 6.5). All solutions were prepared 1 h before injection.
Experimental protocol
After 4 weeks of acclimation and monitoring, rats were randomly divided into one of six treatment groups (n = 12 per group) and were given a single s.c. injection of either saline (4 ml kg-' body weight), acetylsalicylic acid (aspirin, a non-specific PGHS inhibitor, 50 mg kg-'), sodium salicylate (the degradation product of aspirin, 50 mg kg-'), indomethacin (a selective PGHS-1 inhibitor, 4 mg kg-'), nabumetone (a selective PGHS-2 inhibitor, 100 mg kg-') or dmPGE2 (a major colon prostaglandin, 50 mg kg-') on three successive mornings. Aspirin, indomethacin and nabumetone were given in dosages that have significant anti-inflammatory action and that would significantly inhibit PG biosynthesis (Meade et al, 1993 ; Laneuville et al, 1994) . DmPGE2 was administered at a dose that has been shown to confer mucosal protection against NSAIDinduced injury in the gastrointestinal tract (Lee and Feldman, 1992) . On the fourth morning, half of the rats in each group (n = 6) were given a s.c. injection of DMH (12 mg base per kg bw) and the other half were injected with DMH vehicle alone (4 ml kg-'). This weekly pattern was repeated for 8 weeks according to an established protocol for inducing rat colon cancer (Cameron et al, 1990) . At the start of week 9 (i.e. 3 days after the last DMH dose), the rats were anaesthetized and killed by decapitation. Immediately after killing, each colon was resected, rinsed with ice-cold phosphate-buffered saline (PBS, pH 7.4) and examined macroscopically. A 2-cm length of bowel was flash-frozen in liquid nitrogen and stored at -80°C for radioimmunoassay of cyclooxygenase activity, as described previously (Redfern et al, 1987; Lee and Feldman, 1992) , using the formation of PGE2 from radiolabelled arachidonic acid as an end point. The remaining distal colon was stretched to remove longitudinal folds and pinned flat, serosa side down, on a piece of cork board. The pinned colons were fixed in 10% buffered formalin for 2 h, then stored in 70% ethanol. Rats that received DMH gained significantly less weight (P < 0.05) than the DMH vehicle control rats during this 8-week period (82.8 ± 9.89 and 118 ± 8.11 g ± s.e.m. respectively), but there was no significant difference in weight gain due to the other drug treatments (data not shown).
Proliferative analyses
Transverse segments of the rat descending colon were excised from approximately 3 cm proximal to the anus through the distal colon ALN (over the distal ALN) and from 6 cm proximal to the ALN) and from approximately 3 cm proximal to the anus through the distal colon ALN (over the ALN), and prepared for histology. Four-,um-thick cross-sections of each paraffin-embedded colon segment were cut, mounted on polylysine-coated glass slides, deparaffinized through a series of xylene and graded ethanol washes and incubated with an anti-PCNA monoclonal antibody using routine immunohistochemical procedures, as previously described (Hardman and Cameron, 1994) . The validity of using PCNA immunohistochemistry for assessment of cell proliferation in the colon epithelium has been reported previously (Risio et al, 1993; Bostick et al, 1994) . As PCNA exhibits a gradation of nuclear staining in formalin-fixed tissue, strict selection criteria were used in which the number and crypt position of only the most intensely stained cells were recorded. Crypts were included in the assessment if they spanned from immediately adjacent to the muscularis mucosae to the surface epithelium, with the entire lumen of the crypt visible. Cell proliferation parameters were scored for at least 12 crypts per rat in each colon region as reported previously (Hardman 1994; Barnes et al, 1995) . A single column of cells was counted in each complete mid-axially sectioned crypt from the base up each side to the mouth of the crypt. The recorded parameters were the following: total height from the base to the mouth of the crypt in number of cells (CH), total number of darkly stained PCNApositive cells per crypt, and position of each positively stained cell along the crypt column.
Scoring of apoptosis
Apoptosis was scored on haematoxylin and eosin-stained, complete mid-axially sectioned colon crypts, as described previously , using different sections from the same tissue blocks used in assessing crypt cell proliferation. At least 30 crypts away from an ALN and 15 crypts over the distal ALN per rat were divided along the long axis into two half-crypts, which were scored separately for each of six rats per treatment group (i.e. at least 360 half-crypts away ALN and 180 half-crypts over ALN). Each apoptotic event was identified using the established morphological features of nuclear marginalization of chromatin, condensation of the cytoplasm, cell shrinkage and membrane blebbing, and final fragmentation of the cell into apoptotic bodies (Potten, 1992 ) using a light microscope (Figure 1 ). ness-of-fit test. However, the square root transformed data did not differ from a normal distribution, so parametric statistical comparisons of PCNA-stained cells per crypt and crypt apoptotic index were performed on the transformed data. Crypt height was found to be normally distributed and thus no transformation was necessary. t-tests between the mean cell position of the transformed frequency distributions of proliferative or apoptotic cell along the length of the colon crypt were used as a measure of central tendency for determining the effect of DMH treatment and/or location over or away from the distal ALN on the intracrypt distribution of proliferative or apoptotic cells. For simplicity of presentation, these frequency distributions were smoothed over five consecutive cell positions along the length of the crypt in Figure 2 . 
Comparison of two methods for identifying apoptotic cells
A comparison between apoptotic counts within the crypt as assessed by morphology and as assessed by in situ end-labelling of the fragmented DNA ends was conducted on colon tissue sections from the DMH vehicle/saline control group. There were quantitative differences in the apoptotic index as assessed by these two methods (Table 2) . Scoring by the morphological criteria gave a higher apoptotic index than the DNA end-labelling method. However, statistical analyses showed that there was no significant difference in the mean of the spatial frequency distribution of apoptotic cells within the crypt due to the method of detection.
Both techniques indicated that the number of apoptotic cells per midaxial crypt section and the mean of the frequency distribution of apoptotic cells were higher in crypts located over the ALN than in crypts away from the ALN. The results of the morphological index were approximately that of the estimated normal rate of apoptosis in mouse colon epithelial cells (0.2 apoptotic bodies/midaxial crypt section; Potten, 1992) . The DNA end-labelling method may identify fewer apoptotic cells than morphology because this technique: (a) exhibits marked variability of results; (b) is highly dependent on the conditions of the labelling procedure; and (c) appears to be difficult to use in the intestine (Que and Gores, 1996) . Owing to the greater accuracy and reliability of morphological criteria, this method was used for identification of apoptotic cells for the quantitative apoptotic data presented in the remainder of this report.
Quantitation of crypt apoptosis as influenced by DMH, NSAIDs or location in the colon
The mean number of apoptotic cells per midaxial colon crypt section in each treatment group were compared by three way ANOVA for differences due to the variables of: (a) DMH treatment; (b) location in colon (over or away from the ALN); and (c) NSAID treatment. DMH treatment did not significantly affect the occurrence of apoptosis in colon epithelial cells as assessed 3 days after the last DMH dose (data not shown), but the mean apoptotic index was significantly higher in crypts located over the distal ALN (0.754 apoptotic cells/crypt section) than in crypts located away from the distal ALN (0.219 apoptotic cells/crypt section) as shown in Table 3 . There was no significant difference between the apoptotic indices of the DMH/NSAID treatment groups away from the ALN. However, over the ALN the mean apoptotic index of the salicylate treated group was significantly higher than in all other treatment groups (P < 0.001).
Correlation of apoptosis and proliferation Linear regression was used to test for correlation between the crypt apoptotic index and the cell proliferative index in crypts of individual treatment groups both with and without DMH and in crypts located over and away from the distal ALN. There were no significant correlations by linear regression analyses between cell birth (proliferation) and cell death (apoptosis) within crypts (data not shown). This lack of correlation may be due to the assessment of apoptotic cells only within the crypt column. Considerable cell death occurs at the luminal surface of the colon epithelium and apoptotic cells on the luminal surface were not assessed. 
Distribution of proliferating cells and apoptotic cells in colon crypts
There were no significant differences between NSAID treatment groups in the distribution of PCNA-positive cells, the distribution of apoptotic cells along the length of the crypt, or in crypt height in number of cells (data not shown). Therefore, distributional data from all treatment groups were combined for analyses of the effects of crypt location (over vs away from ALN) and DMH treatment on the frequency distributions of proliferating cells and of apoptotic cells along the crypt length, and of mean crypt height (Figure 2 ). Proliferative cells were located mainly in the lower one-third to two-thirds of the crypt, whereas apoptotic cells were found at every cell position along the length of the crypt.
Comparison of the means of the distributions of proliferation, apoptosis and crypt height using the t-test showed that the means of all three distributions were higher in crypts located over the ALN than in crypts located away from the ALN whether or not the rats were exposed to DMH (Table 4) . DMH treatment resulted in: (a) a significant shift in the mean position of proliferative cells towards the top of the crypt; (b) a significant shift in the mean position of apoptotic cells towards the base of the crypt; and (c) a significant increase in the mean crypt height (Table 4 ). The magnitude of this DMH effect on the mean position of proliferative and apoptotic cells was similar in crypts over and away from ALN, possibly indicating a similar response to the carcinogen in both regions of the colon.
DISCUSSION
NSAIDs and ALN on cell proliferation Colon crypt epithelial cell proliferation was evaluated at the end of an 8-week initiation period in this rat colon cancer model, specifically 4 days after the last NSAID dose and 3 days after the last DMH dose. This recovery time was necessary to allow the epithelium to reach a steady state after DMH injection (Wright and Alison, 1984; Deschner, 1987; Cameron et al, 1990) , and to enable the evaluation of longer lasting rather than immediate effects of the other drugs. Given the relatively short half-lives of the drugs administered (Insel, 1996) and the lack of any significant difference in total cyclo-oxygenase activity between the treatment groups, any changes in proliferation may have been due to a long-term influence of the NSAID rather than to a short-term NSAID suppression of prostaglandin synthesis. However, 4 days after the last dose there was no significant change in crypt proliferation due to indomethacin, nabumetone or dmPGE2 treatment when compared with the saline/DMH control group. Thus, it is probable that these drugs do not have a long-lasting influence on colon epithelial cell proliferation. There were significant increases in the mean number of proliferating cells per crypt 4 days after salicylate or aspirin treatment, which occurred selectively in crypts located over the ALN, although the saline/DMH control group had a spuriously low PCNA index. The relevance of these findings is discussed below in relation to altered apoptosis within the same colon location and treatment groups. Finally, we would like to point out that although we have used strict counting criteria to avoid excessive proliferative counts, there are potential limitations to using PCNA as a proliferative marker, such as the long half-life of PCNA and its expression during DNA repair, leading to the labelling of nonproliferative cells (Hall et al, 1990; Risio et al, 1994) . Crypt cell proliferation was significantly higher following DMH treatment, and also significantly higher in crypts located over an ALN than in crypts located away from an ALN. These findings were expected based on previous reports (Hardman and Cameron, 1994; Barnes et al, 1995) . As there is a strong correlation between sites of lymphatic nodules and sites of high incidence of colon and rectal tumours in both rodents (Hammann et al, 1992; Cameron et al, 1996) and humans (Shamsuddin et al, 1982; Glick et al, 1988; Hillon et al, 1990) , it seems important to evaluate the ability of potential chemopreventive agents to modulate surrogate end point biomarkers in colon crypts in the region of the ALN if we are to be able to predict the efficacy of the agent at preventing colon cancer.
Alterations in crypt apoptotic index The transformation of colorectal epithelium to carcinoma has been associated with a progressive inhibition of apoptosis Payne et al, 1995) and an increase in the proliferative-apoptotic cell ratio (Koike, 1996) . Apoptosis within the crypt column is thought to eliminate crypt cells containing random and/or induced genetic defects (Potten, 1992) . Perturbation of the normal pattern of apoptosis may, therefore, serve as an early surrogate end point biomarker of both carcinogen exposure and disease progression. We have for the first time used alteration in the number and the distribution of apoptotic cells within rat colon crypts to indicate both early preneoplastic changes and the efficacy of chemopreventive interventions.
The findings reported here reveal an overall significant increase in cell proliferation in the midaxially sectioned colon crypts 3 days after repeated carcinogen exposure without a significant persistent increase in the apoptotic index. Increased proliferation without increased cell death might be expected to result in an accumulation of cells in the crypt column height, which was indeed observed. However, conclusions cannot be drawn from the present data on altered crypt cell volume. It is likely that the observations reported here of an overall increase in proliferation and decrease apoptotic cell death within the crypt column of midaxially sectioned colon crypts reflect a perturbation from the normal crypt homeostasis after repeated carcinogen exposures.
Treatment with aspirin or sodium salicylate resulted in increased proliferation and a higher apoptotic index (significant for salicylate only) selectively in crypts over the distal ALN. Considering the fact that salicylic acid, the metabolite of aspirin, has a much longer biological half-life than does aspirin (Insel, 1996) , and that evaluations were performed 4 days after the last aspirin dose, one can conjecture that the observed aspirin effect may actually be due to exposure to salicylate rather than as a direct action of aspirin itself. In support of this hypothesis, in vitro studies report that salicylate treatment (Elder et al, 1996) but not aspirin treatment (Shiff et al, 1996) induced apoptotic cell death in cultured epithelial cells. Increased epithelial cell turnover rate (apoptosis and proliferation) after carcinogen exposure may be indicative of self-screening, i.e. identification and elimination of cells with irreparable genetic damage, resulting in compensatory increased cell proliferation. Thus, one potential cancer chemopreventive mechanism of action for aspirin may be to increase death of damaged cells via salicylate, specifically in the crypts located over the distal ALN, which are at high risk for developing cancer (Hardman and Cameron, 1994; Cameron et al, 1996) . Indeed, induction of apoptosis has been proposed as the primary mechanism of action of the NSAID sulindac and its sulphide and sulphone derivatives in countering familial adenomatous polyposis Shiff et al, 1995) .
Distribution of proliferative and apoptotic cells within colon crypts DMH appears to effect a long-term (i.e. at least 3 days) coordinated, spatial alteration in the distribution of cell birth and cell death within the crypt. The significant reduction in the relative distance between the peaks of the distribution of cell proliferation and cell death after DMH treatment may be indicative of greater apoptotic cell death of the less differentiated progenitors of epithelial cells that are found deeper in the crypt. Upon repeated carcinogen exposure, crypt stem cells are likely to sustain and accumulate genetic damage, but are hypothesized to be unable to eliminate themselves by undergoing apoptosis due to high levels of Bcl-2 expression (Merritt et al, 1995) . The progeny of stem cells, however, lose this high level of Bcl-2 expression (Merritt et al, 1995) and gain the capacity for self-screening and subsequent elimination of damaged cells through induction of apoptosis. With a greater number of progeny cells dying earlier in the differentiation process, fewer cells remain to repopulate the crypt. Thus, the remaining cells must undergo a greater number of divisions to maintain the normal number of crypt cells. The result is a delay in terminal cell differentiation, the occurrence of proliferating cells higher in the crypt column, and a significant expansion of the crypt proliferative zone after carcinogen exposure (Deschner and Maskens, 1982; Wright and Alison, 1984) . Eventually, some cells with genetic damage are likely to escape this self-screening mechanism, leading to proliferation of carcinogen-initiated cells and the eventual development of intraepithelial neoplasms. Aspirin or salicylate may somehow enhance the self-screening capacity and subsequently the elimination of damaged cells.
CONCLUSION
Aspirin and salicylate are hypothesized to enhance self-screening of DMH-initiated colon epithelial cells selectively in crypts located over the distal aggregate of lymphoid nodules, a site at high risk for adenocarcinoma development, suggesting a possible anti-cancer mechanism of action for aspirin. In the present model of DMH-induced rat colon cancer, administration of indomethacin and nabumetone did not alter surrogate end point biomarkers when evaluated 4 days after the last NSAID dose, suggesting that these NSAIDs may not have the same chemopreventive ability as aspirin. Perturbation of the normal colon crypt apoptotic index and the normal distribution of apoptotic cells within the crypt were successfully used as surrogate biomarkers of colon carcinogen exposure. Given the importance of both cell birth and cell death in the carcinogenic process, colon crypt epithelial cell apoptosis in conjunction with cell proliferation should be evaluated in studies of colon carcinogenesis.
